TY - JOUR T1 - An optimal control policy for COVID-19 pandemic until a vaccine deployment JF - medRxiv DO - 10.1101/2020.09.26.20202325 SP - 2020.09.26.20202325 AU - Hamid R. Sayarshad Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/07/2020.09.26.20202325.abstract N2 - When an outbreak starts spreading, policy makers have to make decisions that affects health of their citizens and the economic. Some might induce harsh measures, such as lockdown. Following a long harsh lockdown, economical declines force policy makers to rethink reopening. But what is the most effective reopening strategy? In order to provide an effective strategy, here we propose a control strategy model. Our model assesses the trade-off between social performance and limited medical resources by determining individuals’ propensities. The proposed strategy also helps decision makers to find optimal lockdown and exit strategy for each region. Moreover, the financial loss is minimized. In addition, a study of a COVID-19 dataset for Los Angeles County is performed to validate our model and its results.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThere is not a clinical data in our work, currently bioRxiv is redirecting papers related to epidemiology to medrxiv. That's the reason we are submitting our work here.Funding StatementThis research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given belowAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request all data will be provided. ER -